COMP <GO>
CBIO vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Crescent Biopharma Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CBIO 1
— ABBV 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $14.07 (+4.22%) • MKT CAP: $522.6M
roic
-35.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBIO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CBIO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.86% | 3.47% | -17.33 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 1.40% | 6.90% | -5.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | — | 8.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.36 | 5.33 | +1.03 | CBIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.1 | 65.1 | -19.01 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $522.6M | $513.86B | -$513.34B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CBIO REV | ABBV REV | CBIO GROSS % | ABBV GROSS % | CBIO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $10.8M | $61.16B | — | 70.2% | -$72.5M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$31.1M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | -$34.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBIO // BETA —
ABBV // BETA 1.15